
**GENERATION OF TOLEROGENIC HUMAN
DC THROUGH RAPAMYCIN
CONDITIONING AND GENETIC
MODIFICATION WITH HLA-G**

A thesis submitted in partial fulfillment of the
PhD degree

in

The Department of Medicine
Faculty of Health Sciences
The University of Adelaide

by

Boris Fedoric

June 2009

Table of contents

Abbreviations	7
Declaration	8
Acknowledgments	9
Thesis Summary	10
CHAPTER 1	12
LITERATURE REVIEW	12
1.1 Organ transplantation – Australian and USA statistics	13
1.2 Immunosuppressive Agents and Tolerance Induction	13
1.3 Dendritic cell immunotherapy	17
1.4 Immunobiology of DC	20
1.4.1 DC origin and differentiation	20
1.4.2 Differential function of immature DC versus mature DC	21
1.4.3 T-Cell Activation	22
1.4.4 The Immunological Synapse	23
1.4.5 CD80 and CD86 in allo-activation and tolerance	25
1.4.6 Th1/Th2 Paradigm in Transplantation	26
1.5 Mechanisms involved in allogeneic T cell Hyporesponsiveness	27
1.5.1 T cell Anergy	28
1.5.2 Apoptosis and Activation Induced Cell Death (AICD)	28
1.5.3 Generation of regulatory T cells (T _{REG})	29
1.6 DC in transplantation	30
1.6.1 Sites of alloantigen presentation by DC	31
1.6.2 Forms of alloantigen presentation by DC	32
1.6.3 Involvement of trogocytosis in immune response	34
1.7 Inhibitory molecules in transplantation	36
1.7.1 Immunoglobulin-like transcript (ILT) 2, ILT3 and ILT4 structure, distribution and ligands	37
1.7.2 Outcome of Immunoglobulin-like transcript (ILT) 2, ILT3 and ILT4 signalling	37
1.7.3 Role of (ILT) 2, ILT3 and ILT4 in alloimmune response	39
1.7.4 Immunobiology and function of HLA-G	40
1.7.4.1 Gene structure of human HLA-G	40
1.7.4.2 Protein structure of human HLA-G	43
1.7.4.3 Expression of HLA-G on Dendritic cells	45
1.7.4.4 HLA-G receptor interactions	46
1.7.4.4.1 KIR2DL4 receptor	46
1.7.4.4.2 CD8 α / α receptor	46
1.8 Immunomodulatory functions of HLA-G molecule	47
1.8.1 HLA-G arrests maturation of APC	47
1.8.2 The effect of HLA-G on T cells	48
1.9 Cell-based tolerogenic therapy for transplantation	50
1.9.1 Pharmacological manipulation of DC	52
1.9.2 Genetic manipulation of DC	54
1.10 The pre-clinical Ovine Model of Renal Transplantation	58
1.11 Study rationale and Hypothesis	59
1.12 Project Aims:	61
CHAPTER 2	64
2.1. General Methods	65
2.1.1. Cell Culture	65
2.1.1.1. Ovine and Human Peripheral Blood Mononuclear Cell (PBMC) Extraction	65
2.1.1.1.1 Human	65
2.1.1.1.2 Ovine	65
2.1.1.2. Human Monocyte Derived Dendritic Cells	66

2.1.1.3. Nylon Wool Isolation of T Cells.....	66
2.1.1.4. Mixed Lymphocyte Reaction	66
2.1.1.5. Cell Lines	67
2.1.2. Molecular Biology Methods	67
2.1.2.1. Total RNA Extraction	67
2.1.2.2. Reverse Transcription (RT)	68
2.1.2.3. Polymerase Chain Reaction (PCR)	68
2.1.2.4. Agarose Gel Electrophoresis	69
2.1.2.5. Endonuclease Restriction Digestion of DNA	70
2.1.2.6. Agarose Gel Purification of Restriction Digest Products	70
2.1.2.7. Ultraclean™ Purification of DNA	71
2.1.2.8. Ligation of DNA Fragments into Cloning Vectors.....	71
2.1.2.9. Preparation of Competent E.coli TG1α and DH10B Bacterial Cells	71
2.1.2.10. Transformation of Competent <i>E.coli</i> Cells	72
2.1.2.11. Plasmid Mini-preparation (Mini-prep).....	72
2.1.2.12. Plasmid Midi-preparation (Midi-prep).....	73
2.1.2.13 DNA Sequencing	74
2.1.3. Adenoviral Methods	74
2.1.3.1. Preparation of Electrocompetent BJ5183 Cells.....	74
2.1.3.2. Generation of pADEasier-1 BJ5183 Bacterial Cells	75
2.1.3.3. Electroporation of BJ5183 cells with pAdTrack-CMV	75
2.1.3.4 Screening of Colonies for Homologous Recombination.....	75
2.1.3.5. Transformation of DH10β E.coli Cells.....	76
2.1.3.6. LipofectAMINE™ Transfection of Adenoviral Constructs into HEK 293 Cells	77
2.1.3.7. Preparation of Adenoviral HEK 293 cell lysates.....	77
2.1.3.8. Infection of HEK 293 Cells and Scale-up Viral Production	78
2.1.3.9. MustangQ Purification of Adenoviral Particles.....	79
2.1.3.10. Fluorescence Quantification of Adenoviral Titres	79
2.1.4. Flow Cytometry	80
2.1.4.1. Cell surface staining	80
2.1.5. Histochemistry	81
2.1.5.1. Biopsy Preparation	81
2.1.5.2. Hematoxylin and Eosin Staining	81
2.1.5.3. Immunohistochemistry	82
2.2 Centrifuges	83
CHAPTER 3	84
3.1 Introduction	85
3.2 Materials and Methods	87
3.2.1. DC preparation and treatment with immunomodulatory agents.....	87
3.2.2 Flowcytometry.....	89
3.2.3 Mixed lymphocyte reaction (MLR)	90
3.2.4. FoxP3 analysis in T cells co-cultured with modified DC	90
3.2.5 RT-PCR analysis.....	91
3.2.6 Statistical analysis.....	92
3.3. Results	92
3.3.1 Baseline expression profile of costimulatory molecules on DC during their differentiation and maturation.....	92
3.3.2 Rapamycin downregulates the expression of both positive costimulatory molecules and inhibitory receptors during DC differentiation.....	94
3.3.3 Rapamycin-treated DC inhibit T cell proliferation in a DC-MLR with moderate changes to FoxP3 expression in T cells	97
3.3.4 Rapamycin-treated mature DC inhibit T cell proliferation in a DC-MLR with minor changes to FoxP3 expression in T cells	97
3.3.5 Rapamycin treatment of mature DC does not affect the expression of positive costimulatory molecules on these DC	99

3.3.6 Rapamycin treatment of mature DC at day 7 induces the expression IDO mRNA on these DC	102
3.4 Discussion	104
CHAPTER 4	111
4.1 Introduction	112
4.1.1 The NOD/SCID model	112
4.1.2 Ovine DC: characterisation and enrichment from lymphatic cannulation	114
4.2. Methods	115
4.2.1 Lymph node removal	115
4.2.2 Cannulation	116
4.2.3 Histodenz Purification of ovine DC from lymph	118
4.2.4 RAPA treatment of ovine DC	118
4.2.5 Flowcytometry	119
4.2.6 DC-Mixed Lymphocyte Reaction	119
4.2.7 DC viability	119
4.2.8 Excision of ovine skin for engraftment in NOD/SCID	120
4.2.9 NOD/SCID mice	120
4.2.10 Engraftment of ovine skin onto NOD/SCID mice	120
4.2.11 CFSE labelling of PBMC	122
4.2.12 Intra-peritoneal challenge with allogeneic ovine PBMC and DC	123
4.2.13 Histological Analysis of Skin Biopsies	123
4.2.14 Immunohistological analysis of Skin Biopsies	124
4.2.15 Rejection Scores	124
4.2.16 RNA Extraction from skin biopsies and PCR analysis for cytokine mRNA expression	125
4.3. Results	125
4.3.1 Ovine DC output from cannulated pseudo-afferent lymphatics	125
4.3.2 Phenotype of ovine DC obtained from pseudo-afferent lymphatic cannulation	130
4.3.3 Stimulatory capacity of ovine DC	130
4.3.4 RAPA-treated ovine DC exhibit tolerogenic properties <i>in vitro</i>	130
4.3.5 Ovine skin rejection upon allogeneic challenge with DC and PBMC mixture in NOD/SCID mice	133
4.3.6 The effect of RAPA-DC on ovine skin allograft rejection in NOD/SCID mice	136
4.3.7 The effect of RAPA-DC on cytokine response in rejecting skin	139
4.4 Discussion	141
CHAPTER 5	146
5.1 Introduction	147
5.2 Materials and Methods	151
5.2.1 Bioinformatics analysis of HLA-G1 and HLA-G5	151
5.2.2 Primer design and PCR amplification of HLA-G1 and HLA-G5	152
5.3.3 Screening of bacterial colonies for HLA-G expression using PCR technique	153
5.3.4 Cloning of HLA-G1 and HLA-G5	153
5.3.4.1 pGEM-T-Easy	153
5.3.4.2 pAdTrack-CMV	153
5.3.4.3 Sequencing of inserts from pAdTrack-CMV vector	154
5.3.4.4 Homologous recombination	155
5.3.4.5 Production of Adenoviral particles	155
5.3.5 Quantification of Adenoviral Titres	155
5.3.6 Transfection of dendritic cells	156
5.3.7 RNA extraction from DC	156
5.3.8 Polymerase Chain Reaction (PCR)	157
5.3.9 Flowcytometry for detecting HLA-G1 expression	157
5.3.10 HLA-G5 ELISA	158
5.4 Results	158
5.4.1 PCR amplification of HLA-G1 and HLA-G5 from Jeg-3 cell line	158
5.4.2 Cloning of HLA-G1 and HLA-G5 in pGEM-T Easy Vector	160
5.4.3 HLA-G1 and HLA-G5 cloning in pAdTrack-CMV	162

5.4.4 Confirmation of HLA-G1 and HLA-G5 orientation in pAdTrack-CMV	162
5.4.5 Sequencing analysis of HLA-G1 and HLA-G5 from pAdTrack-CMV	165
5.4.6 Generation of pAdEasier-1 BJ5183 E. coli	165
5.4.7 Confirmation of homologous recombination	168
5.4.8 Detection of HLA-G1 and HLA-G5 expression	168
5.5 Discussion	172
CHAPTER 6	175
6.1 Introduction	176
6.2 Materials and Methods	178
6.2.1 Mixed lymphocyte reaction (MLR)	178
6.2.2 Addition of purified HLA-G to the MLR	179
6.2.3 Enrichment of CD4⁺ T cells	179
6.2.4 Co-culture of transfected DC and CD4⁺ T cells	180
6.2.5 Flowcytometry for detecting trogocytosis	180
6.2.6 ILT2-Fc binding	181
6.2.7 Trogocytosis time course	181
6.2.8 Immunomagnetic isolation of CD3⁺ T cells	182
6.2.9 T cell proliferation assay	182
6.2.10 T_{APC} assay	183
6.2.11 Statistical analysis	183
6.3 Results	183
6.3.1 DC transfectants express structurally functional membrane bound HLA-G	183
6.3.2 Allogeneic T cells acquire HLA-G1 from transfected DC via trogocytosis and suppress proliferation of bystander autologous T cells	184
6.3.3 T cell proliferation and CD80/86 signalling are important for trogocytosis	187
6.3.4 T cells acquire attenuated APC properties from tolerogenic RAPA-DC	189
6.3.5 Combination of pharmacological and genetic modification of DC further reduced proliferative and T_{APC} properties of T cells	191
6.4 Discussion	193
CHAPTER 7	200
7.1 Concluding Remarks and Future Directions	201
Materials	208
Solutions and Buffers	215
APPENDIX	222
REFERENCES	239

Notes:

Abbreviations

<i>Abbreviation</i>	<i>Expanded meaning</i>
AdV	Adenovirus
AICD	Activation Induced Cell Death
APC	Antigen Presenting Cells
CD	Cluster of Differentiation
CMV	Cytomegalovirus
CPM	Counts Per Minute
CsA	Cyclosporin A
DC	Dendritic cell
DMEM	Dulbecco's Modified Eagle Medium
FCS	Foetal Calf Serum
g	Gravity
GM-CSF	Granulocyte Macrophage Colony Stimulating Factor
Gy	Greys
H&E	Hematoxylin and Eosin
HEK	Human Embryonic Kidney
HLA-G	Human Leukocyte Antigen G
IDO	Indoleamine 3,3-Dioxygenase
IFN	Interferon
IL	Interleukin
ILT	Immunoglobulin-like Transcript
mAb	Monoclonal antibody
MFI	Mean Fluorescence Intensity
MHC	Major Histocompatibility Complex
MLR	Mixed Lymphocyte reaction
NOD	Non obese diabetic
PBMC	Peripheral Blood Mononuclear Cells
PBS	Phosphate Buffered Saline
PCR	Polymerase Chain Reaction
PHA	phytohaemagglutinin
RAPA	Rapamycin
RPM	Revolutions Per Minute
RPMI	Roswell Park Memorial Institute
SCID	Severe Combined Immunodeficiency
Th	T helper cell
Treg	T regulatory cell

Declaration

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution to Boris Fedoric and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968. The author acknowledges that copyright of published works contained within this thesis (as listed below*) resides with the copyright holder(s) of those works. I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue, the Australasian Digital Theses Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

*List of publications

- The following research article is published:
“Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of FoxP3 induction” *Immunol Lett.* 2008 Oct 30;120(1-2):49-56.
- The following abstracts have been published:
 - Fedoric, B *et al.*. *Immunology and Cell Biology*, Vol. 84 Issue 3 Page A1 June 2006
 - Fedoric, B *et al.*. *American Journal of Transplantation*, Vol. 7 Supplement 2 Page 410 May 2007

.....
Boris Fedoric

.....
Dr Ravi Krishnan

Acknowledgments

Firstly, I would like to acknowledge my supervisor Dr Ravi Krishnan for his unconditional support, productive discussions and brilliant ideas. It was my pleasure and privilege to be a part of your team and work in such a stimulating environment. I would also like to thank you for all your dedication and time that you invested in me - all of these things have made me a better scientist. You have provided me with great knowledge for the future and opened doors for my scientific success.

Secondly, I would like to acknowledge the support of the University of Adelaide and The Queen Elizabeth Research foundation for the provision of a scholarship which has enabled me to undertake my PhD.

Additional acknowledgment goes to Prof. Graeme Russ and A/Prof. Toby Coates for their unconditional support throughout my PhD and for providing a great reference during my job hunting.

I would also like to acknowledge Julie Johnston, Svjetlana Kireta, Dr Ashley Newland, and Darling Rojas, for their constructive feedback and help in the lab.

An enormous “thank you” goes to my partner Samantha Rella for her constant encouragement, support and understanding, as well as for free psychological counselling when things got tuff. Thank you for being there for me it meant a lot!!!

Special acknowledgements go to my parents, Milena and Mile Fedoric, and my brother, Srdjan Fedoric, for their constant support, help and positive attitude. Also, I would like to extend my acknowledgments to my second family, Silvia and Mauro Rella for their constant support.

Thesis Summary

Dendritic cells (DC) are potent antigen presenting cells involved in the initiation of the alloimmune response and organ transplant rejection. This thesis, has investigated pharmacological and genetic approaches to manipulate DC in order to generate tolerogenic DC which elicit poor allostimulatory activity as potential cell therapy agents to treat allograft rejection.

In the first aspect of this study, human monocyte-derived DC were used to study the influence of Rapamycin (RAPA) on DC phenotype and function. This study showed that RAPA when added to monocytes prior to DC differentiation or after DC maturation generated tolerogenic DC as evidenced by the ability of these cells to induce T cell hyporesponsiveness. However, T cell hyporesponsiveness was associated with downregulation of costimulatory molecules only when added prior to differentiation and surprisingly was not influenced by the induction of CD4⁺FoxP3⁺ T cells. To assess the effects of RAPA on DC function in the transplant setting an *in vivo* chimeric model of ovine vascularised skin allograft transplantation was established in immunocompromised NOD/SCID mice as a host. This model was established as a preliminary model to acquire *in vivo* data prior to testing the effect of pharmacologically modified DC in the preclinical ovine model of renal allograft transplantation, also established in the host laboratory. Firstly, comparison of ovine DC obtained from cannulation of the prefemoral lymphatic vessels in sheep demonstrated that RAPA-modified ovine DC acted as poor stimulators of allogeneic ovine T cells similar to human DC treated with RAPA. Secondly, in NOD/SCID mice engrafted with ovine skin, the infusion of allogeneic ovine T cells together with RAPA-modified ovine DC reduced histological rejection in comparison to control DC.

In the second aspect of this study, the effects of genetic manipulation of DC were investigated. In order to investigate the effects of genetic modification of DC, two isoforms of the human HLA-G molecule, HLA-G1 (membrane bound) and HLA-G5 (soluble isoform) were used to generate adenoviral vectors. Unexpectedly, both HLA-G isoforms expressed by human DC transfectants were unable to induce allogeneic T cell hyporesponsiveness in the mixed lymphocyte reaction (MLR). Surprisingly, in the MLR the allogeneic T cells acquired HLA-G1, but not HLA-G5, indicating that direct cell contact and membrane transfer from DC to T cells occurred (Trogocytosis). In addition to HLA-G1, costimulatory molecules (CD40, CD80, CD86 and MHC Class II) were also co-transferred from DC to allogeneic T cells. Accordingly, in secondary proliferation assays T cells immunoselected after co-culture with allogeneic untransfected DC (T_{UT}) demonstrated potent antigen presenting activity when used as stimulators of autologous T cells (analogous to the indirect pathway of antigen presentation). In contrast to T_{UT} , immunoselected T cells that acquired HLA-G1 (T_{HLA-G1}) upon co-culture with DC-transfectants showed poor stimulatory capacity. Thus the data reported in this thesis supports the proposed novel concept that HLA-G acquired by T cells through genetically modified DC, functions to autoregulate T cells via T-T cell interaction through the HLA-G receptor ILT2 (negative signalling receptor) expressed on T cells.

In conclusion, this thesis has firstly provided supportive evidence that the pharmacological modification of human and ovine DC with RAPA has potential therapeutic effects on allograft rejection. Secondly, the genetic modification of DC to induce expression of HLA-G has specifically allowed the transfer of this molecule to T cells by trogocytosis and the inhibition of alloreactive T cell expansion.